| P2093 | author name string | Jürgen Kuball | |
| | Wouter Scheper | |
| | Zsolt Sebestyen | |
| P2860 | cites work | Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB | Q22009950 |
| | Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA | Q22010440 |
| | Granulysin‐Dependent Killing of Intracellular and ExtracellularMycobacterium tuberculosisby Vγ9/Vδ2 T Lymphocytes | Q56827951 |
| | Phenotype markers and cytokine intracellular production by CD8+ gammadelta T lymphocytes do not support a regulatory T profile in Behçet's disease patients and healthy controls | Q56899634 |
| | Phase-I study of Innacell γδ™, an autologous cell-therapy product highly enriched in γ9δ2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma | Q57949352 |
| | Regulation of IgE responses to inhaled antigen in mice by antigen-specific gamma delta T cells | Q59310681 |
| | Harnessing γδ T cells in anticancer immunotherapy | Q59387577 |
| | Cytomegalovirus and tumor stress surveillance by binding of a human γδ T cell antigen receptor to endothelial protein C receptor | Q60241555 |
| | A major fraction of human intraepithelial lymphocytes simultaneously expresses the γ/δ T cell receptor, the CD8 accessory molecule and preferentially uses the Vδ1 gene segment | Q63968530 |
| | Tissue localization and CD8 accessory molecule expression of T gamma delta cells in humans | Q69737613 |
| | Clonal expansions of V delta 1+ and V delta 2+ cells increase with age and limit the repertoire of human gamma delta T cells | Q72119438 |
| | Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma | Q72133128 |
| | T-cell receptor V delta gene usage by tumour reactive gamma delta T lymphocytes infiltrating human lung cancer | Q72362062 |
| | Release of LL-37 by activated human Vgamma9Vdelta2 T cells: a microbicidal weapon against Brucella suis | Q79174467 |
| | Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation | Q80196080 |
| | Professional antigen-presentation function by human gammadelta T Cells | Q81810232 |
| | Distinct gene expression in human Vdelta1 and Vdelta2 gammadelta T cells following non-TCR agonist stimulation | Q82307107 |
| | Re-targeting T-cells against cancer by gene-transfer of tumor-reactive receptors | Q83654884 |
| | Toll-like receptor expression and function in subsets of human gammadelta T lymphocytes | Q84456947 |
| | Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors | Q85012142 |
| | γδT cells elicited by CMV reactivation after allo-SCT cross-recognize CMV and leukemia | Q85818563 |
| | γ9 and δ2CDR3 domains regulate functional avidity of T cells harboring γ9δ2TCRs | Q87389135 |
| | MICA engagement by human Vgamma2Vdelta2 T cells enhances their antigen-dependent effector function | Q24291528 |
| | Recognition of stress-induced MHC molecules by intestinal epithelial gammadelta T cells | Q24316370 |
| | Key implication of CD277/butyrophilin-3 (BTN3A) in cellular stress sensing by a major human γδ T-cell subset | Q24339540 |
| | Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia | Q24594920 |
| | Adoptive cell transfer: a clinical path to effective cancer immunotherapy | Q24644774 |
| | Cancer regression in patients after transfer of genetically engineered lymphocytes | Q24654976 |
| | Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes | Q24676216 |
| | What lessons can be learned from γδ T cell-based cancer immunotherapy trials? | Q26849323 |
| | Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy | Q26993238 |
| | γδ-T cells: an unpolished sword in human anti-infection immunity | Q26994963 |
| | Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma | Q27005902 |
| | Six-of-the-best: unique contributions of γδ T cells to immunology | Q27010451 |
| | γδ T cells for cancer immunotherapy: A systematic review of clinical trials | Q27021705 |
| | Crystal structure of a T-cell receptor specific for the human MHC class I homolog MICA | Q27666700 |
| | The Intracellular B30.2 Domain of Butyrophilin 3A1 Binds Phosphoantigens to Mediate Activation of Human Vγ9Vδ2 T Cells | Q27682926 |
| | CD1d-lipid antigen recognition by the γδ TCR | Q27686847 |
| | Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 |
| | The human antimicrobial and chemotactic peptides LL-37 and alpha-defensins are expressed by specific lymphocyte and monocyte populations | Q28142106 |
| | Regulation of cutaneous malignancy by gammadelta T cells | Q28188439 |
| | KIR: diverse, rapidly evolving receptors of innate and adaptive immunity | Q28203441 |
| | The biology of NKT cells | Q28277482 |
| | Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer | Q28659468 |
| | Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 | Q29616128 |
| | Chimeric antigen receptor-modified T cells for acute lymphoid leukemia | Q29620130 |
| | A rapid crosstalk of human gammadelta T cells and monocytes drives the acute inflammation in bacterial infections | Q33410795 |
| | Cytomegalovirus-induced gammadelta T cells associate with reduced cancer risk after kidney transplantation | Q33562231 |
| | Human cytomegalovirus elicits fetal gammadelta T cell responses in utero | Q33795023 |
| | CD1-mediated gamma/delta T cell maturation of dendritic cells | Q33963163 |
| | gammadelta T cell subsets: a link between TCR and function? | Q34005647 |
| | Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 | Q34360292 |
| | Redirecting αβ T cells against cancer cells by transfer of a broadly tumor-reactive γδT-cell receptor | Q39544028 |
| | NKG2D costimulates human V gamma 9V delta 2 T cell antitumor cytotoxicity through protein kinase C theta-dependent modulation of early TCR-induced calcium and transduction signals. | Q39698695 |
| | The MHC class Ib protein ULBP1 is a nonredundant determinant of leukemia/lymphoma susceptibility to gammadelta T-cell cytotoxicity | Q39748029 |
| | Tumor-infiltrating gammadelta T cells suppress T and dendritic cell function via mechanisms controlled by a unique toll-like receptor signaling pathway | Q40101993 |
| | Phase I study of bromohydrin pyrophosphate (BrHPP, IPH 1101), a Vgamma9Vdelta2 T lymphocyte agonist in patients with solid tumors | Q40356007 |
| | Activation of V gamma 9V delta 2 T cells by NKG2D. | Q40388491 |
| | Phosphostim-activated gamma delta T cells kill autologous metastatic renal cell carcinoma. | Q40468302 |
| | Safety profile and anti-tumor effects of adoptive immunotherapy using gamma-delta T cells against advanced renal cell carcinoma: a pilot study. | Q40474302 |
| | Killing of laminin receptor-positive human lung cancers by tumor infiltrating lymphocytes bearing gammadelta(+) t-cell receptors | Q41206773 |
| | Tumor cell recognition by γδ T lymphocytes: T-cell receptor vs. NK-cell receptors | Q42086300 |
| | Cutting Edge: γδ T Cells Provide Help to B Cells with Altered Clonotypes and Are Capable of Inducing Ig Gene Hypermutation | Q42798925 |
| | In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients | Q43057295 |
| | V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. | Q43162657 |
| | A phase I study of adoptive immunotherapy for recurrent non-small-cell lung cancer patients with autologous gammadelta T cells | Q43170735 |
| | Gammadelta T cells and the lymphoid stress-surveillance response | Q43496487 |
| | Breakthrough of the year 2013. Cancer immunotherapy | Q43822796 |
| | Cutting edge: TGF-beta1 and IL-15 Induce FOXP3+ gammadelta regulatory T cells in the presence of antigen stimulation | Q44305783 |
| | Gammadelta T cells for immune therapy of patients with lymphoid malignancies | Q44353687 |
| | Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. | Q44575984 |
| | Differentiation, phenotype, and function of interleukin-17-producing human Vγ9Vδ2 T cells. | Q44671613 |
| | Reciprocal activating interaction between dendritic cells and pamidronate-stimulated gammadelta T cells: role of CD86 and inflammatory cytokines | Q45195924 |
| | Early human cytomegalovirus replication after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients | Q45366854 |
| | Efficient killing of human colon cancer stem cells by gammadelta T lymphocytes. | Q46004947 |
| | Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. | Q46028184 |
| | Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy | Q46240502 |
| | Immune suppression by gammadelta T-cells as a potential regulatory mechanism after cancer vaccination with IL-12 secreting dendritic cells | Q50783387 |
| | Age-associated alteration of γδ T-cell repertoire and different profiles of activation-induced death of Vδ1 and Vδ2 T cells | Q51423603 |
| | CXCR5 identifies a subset of Vgamma9Vdelta2 T cells which secrete IL-4 and IL-10 and help B cells for antibody production | Q51978896 |
| | Human peripheral gammadelta T cells possess regulatory potential | Q52908064 |
| | Differentiation of human peripheral blood Vδ1+ T cells expressing the natural cytotoxicity receptor NKp30 for recognition of lymphoid leukemia cells. | Q54367882 |
| | Gammadelta T cells: functional plasticity and heterogeneity | Q34659133 |
| | Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours | Q35208161 |
| | Pilot trial of interleukin-2 and zoledronic acid to augment γδ T cells as treatment for patients with refractory renal cell carcinoma | Q35226178 |
| | Alpha/beta- and gamma/delta TCR(+) lymphocyte infiltration in necrotising choroidal melanomas | Q35311221 |
| | Human gammadelta T lymphocytes induce robust NK cell-mediated antitumor cytotoxicity through CD137 engagement | Q35883004 |
| | Small intestinal CD8+TCRgammadelta+NKG2A+ intraepithelial lymphocytes have attributes of regulatory cells in patients with celiac disease. | Q36227215 |
| | Human intestinal Vdelta1+ lymphocytes recognize tumor cells of epithelial origin | Q36366439 |
| | Self-recognition of CD1 by gamma/delta T cells: implications for innate immunity | Q36368376 |
| | Human T cell receptor gammadelta cells recognize endogenous mevalonate metabolites in tumor cells | Q36370502 |
| | Gamma delta T cells provide an early source of interferon gamma in tumor immunity | Q36371404 |
| | Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells | Q36402321 |
| | Shared reactivity of V{delta}2(neg) {gamma}{delta} T cells against cytomegalovirus-infected cells and tumor intestinal epithelial cells | Q36403003 |
| | γδT17 cells promote the accumulation and expansion of myeloid-derived suppressor cells in human colorectal cancer. | Q36473289 |
| | Tumor-derived γδ regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence | Q36625669 |
| | Nonpeptide antigens, presentation mechanisms, and immunological memory of human Vgamma2Vdelta2 T cells: discriminating friend from foe through the recognition of prenyl pyrophosphate antigens | Q36732656 |
| | Relapse after allogeneic hematopoietic cell therapy. | Q36799799 |
| | Tumor-Infiltrating γδ T Lymphocytes Predict Clinical Outcome in Human Breast Cancer | Q36800215 |
| | CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia | Q37098861 |
| | Cross-presenting human gammadelta T cells induce robust CD8+ alphabeta T cell responses | Q37114832 |
| | The influence of IgE-enhancing and IgE-suppressive gammadelta T cells changes with exposure to inhaled ovalbumin | Q37266990 |
| | Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer | Q37373983 |
| | Uncoupling T-cell expansion from effector differentiation in cell-based immunotherapy | Q37561102 |
| | Antibody-modified T cells: CARs take the front seat for hematologic malignancies | Q37723469 |
| | Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity | Q37764294 |
| | Modulation of γδ T cell responses by TLR ligands | Q37874203 |
| | Anti-CD20 Antibody Therapy for B-Cell Lymphomas | Q38012522 |
| | The natural and the inducible: interleukin (IL)-17-producing γδ T cells | Q38069721 |
| | Regulatory functions of γδ T cells | Q38088501 |
| | Immunotherapy with gene-modified T cells: limiting side effects provides new challenges. | Q38117268 |
| | Hunting for clinical translation with innate-like immune cells and their receptors | Q38171917 |
| | Insights into the Relationship between Toll Like Receptors and Gamma Delta T Cell Responses | Q38240851 |
| | IL-17A produced by γδ T cells promotes tumor growth in hepatocellular carcinoma. | Q39024081 |
| | Inhibition of R5-tropic HIV type-1 replication in CD4⁺ natural killer T cells by γδ T lymphocytes | Q39324337 |
| | Human γδ T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells | Q39411262 |
| P921 | main subject | immunotherapy | Q1427096 |
| P304 | page(s) | 601 | |
| P577 | publication date | 2014-11-20 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Cancer Immunotherapy Using γδT Cells: Dealing with Diversity | |
| P478 | volume | 5 | |